A negative allosteric modulator for α5 subunit- containing GABA receptors exerts a rapid and persistent antidepressant-like action without the side effects of the NMDA receptor antagonist ketamine in mice

eNeuro

Volumn 4, Issue 1, 2017, Pages

  Zanos, Panos ^a   Nelson, Mackenzie E ^a   Highland, Jaclyn N ^a   Krimmel, Samuel R ^a   Georgiou, Polymnia ^a   Gould, Todd D ^a   Thompson, Scott M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Behavior; Depression; GABA NAM; Ketamine; oscillation

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 AMINOBUTYRIC ACID RECEPTOR; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; FLUOXETINE; KETAMINE; MRK 016; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; UNCLASSIFIED DRUG; 2,3-DIOXO-6-NITRO-7-SULFAMOYLBENZO(F)QUINOXALINE; 4 AMINOBUTYRIC ACID A RECEPTOR; AMINO ACID RECEPTOR AFFECTING AGENT; GABRA5 PROTEIN, MOUSE; ISOXAZOLE DERIVATIVE; QUINOXALINE DERIVATIVE; TRIAZINE DERIVATIVE;

ALLOSTERISM; ANIMAL EXPERIMENT; ARTICLE; CONDITIONED PLACE PREFERENCE TEST; CONTROLLED STUDY; DEPRESSION; ELECTROENCEPHALOGRAPHY; EXPERIMENTAL BEHAVIORAL TEST; FAMALE URINE SNIFFING TEST; FEMALE; FORCED SWIM TEST; IMMOBILIZATION STRESS; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; PREPULSE INHIBITION DISRUPTION TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; ROTAROD TEST; SYNAPTIC TRANSMISSION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CONDITIONING; DEPRESSIVE DISORDER; DISEASE MODEL; DRUG EFFECTS; GAMMA RHYTHM; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; PREPULSE INHIBITION;

ALLOSTERIC REGULATION; ANIMALS; ANTIDEPRESSIVE AGENTS; CONDITIONING (PSYCHOLOGY); DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID AGENTS; GAMMA RHYTHM; ISOXAZOLES; KETAMINE; MALE; MICE, INBRED C57BL; MOTOR ACTIVITY; PREPULSE INHIBITION; QUINOXALINES; RECEPTORS, AMPA; RECEPTORS, GABA-A; TRIAZINES;

EID: 85029851700     PISSN: None     EISSN: 23732822     Source Type: Journal    
DOI: 10.1523/ENEURO.0285-16.2017     Document Type: Article

References (43)

1. Atack JR, Maubach KA, Wafford KA, O’Connor D, Rodrigues AD, Evans DC, Tattersall FD, Chambers MS, MacLeod AM, Eng WS, Ryan C, Hostetler E, Sanabria SM, Gibson RE, Krause S, Burns HD, Hargreaves RJ, Agrawal NG, McKernan RM, Murphy MG, et al., (2009) In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1, 2, 4-triazol-5-ylmethoxy)-pyrazolo[1, 5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. J Pharmacol Exp Ther 331:470-484.
2. Autry AE, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature 475:91-95.
3. Ballard TM, Knoflach F, Prinssen E, Borroni E, Vivian JA, Basile J, Gasser R, Moreau JL, Wettstein JG, Buettelmann B, Knust H, Thomas AW, Trube G, Hernandez MC (2009) RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors. Psychopharmacology (Berl) 202:207-223.
4. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
5. Browne CA, Lucki I (2013) Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 4:161
6. Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, Zarate CA Jr (2012) Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry 72:555-561.
7. Driesen NR, McCarthy G, Bhagwagar Z, Bloch MH, Calhoun VD, D’Souza DC, Gueorguieva R, He G, Leung HC, Ramani R, Anticevic A, Suckow RF, Morgan PT, Krystal JH (2013) The impact of NMDA receptor blockade on human working memory-related pre frontal function and connectivity. Neuropsychopharmacology 38: 2613-2622.
8. Dwyer JM, Duman RS (2013) Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry Jun 15;73(12):1189-1198.
9. Farber NB, Newcomer JW, Olney JW (1998) The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer’s disease. Prog Brain Res 116:421-437.
10. Fischell J, Van Dyke AM, Kvarta MD, LeGates TA, Thompson SM (2015) Rapid antidepressant action and restoration of excitatory synaptic strength after chronic stress by negative modulators of alpha5-containing GABAA receptors. Neuropsychopharmacology 40:2499-2509.
11. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ (2009) What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 60:1439-1445.
12. Ghoneim MM, Hinrichs JV, Mewaldt SP, Petersen RC (1985) Ketamine: behavioral effects of subanesthetic doses. J Clin Psycho-pharmacol 5:70-77.
13. Homayoun H, Moghaddam B (2007) NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27:11496-11500.
14. Hunt MJ, Falinska M, Łeski S, Wójcik DK, Kasicki S (2011) Differential effects produced by ketamine on oscillatory activity recorded in the rat hippocampus, dorsal striatum and nucleus accumbens. J Psychopharmacol 25:808-821.
15. Irifune M, Shimizu T, Nomoto M (1991) Ketamine-induced hyperlocomotion associated with alteration of presynaptic components of dopamine neurons in the nucleus accumbens of mice. Pharmacol Biochem Behav 40:399-407.
16. Kallarackal AJ, Kvarta MD, Cammarata E, Jaberi L, Cai X, Bailey AM, Thompson SM (2013) Chronic stress induces a selective decrease in AMPA receptor-mediated synaptic excitation at hippocampal temporoammonic-CA1 synapses. J Neurosci 33:15669-15674.
17. Kittelberger K, Hur EE, Sazegar S, Keshavan V, Kocsis B (2012) Comparison of the effects of acute and chronic administration of ketamine on hippocampal oscillations: relevance for the NMDA receptor hypofunction model of schizophrenia. Brain Struct Funct 217:395-409.
18. Koike H, Chaki S (2014) Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res 271:111-115.
19. Koike H, lijima M, Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224:107-111.
20. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959-964.
21. Lim BK, Huang KW, Grueter BA, Rothwell PE, Malenka RC (2012) Anhedonia requires MC4R-mediated synaptic adaptations in nucleus accumbens. Nature 487:183-189.
22. Maeng S, Zarate CA, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63: 349-352.
23. Malherbe P, Sigel E, Baur R, Persohn E, Richards JG, Möhler H (1990) Functional expression and sites of gene transcription of a novel alpha subunit of the GABAA receptor in rat brain. FEBS Lett 260:261-265.
24. Malkesman O, Scattoni ML, Paredes D, Tragon T, Pearson B, Shaltiel G, Chen G, Crawley JN, Manji HK (2010) The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biol Psychiatry 67:864-871.
25. Mansbach RS, Geyer MA (1991) Parametric determinants in prestimulus modification of acoustic startle: interaction with ketamine. Psychopharmacology (Berl) 105:162-168.
26. Middleton S, Jalics J, Kispersky T, Lebeau FE, Roopun AK, Kopell NJ, Whittington MA, Cunningham MO (2008) NMDA receptor- dependent switching between different gamma rhythm-generating microcircuits in entorhinal cortex. Proc Natl Acad Sci USA 105: 18572-18577.
27. Morgan CJ, Curran HV, Independent Scientific Committee on Drugs (2012) Ketamine use: a review. Addiction 107:27-38.
28. Morgan CJ, Monaghan L, Curran HV (2004) Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 99:1450-1461.
29. Papazoglou A, Soos J, Lundt A, Wormuth C, Ginde VR, Muller R, Henseler C, Broich K, Xie K, Ehninger D, Haenisch B, Weiergräber M (2016) Gender-specific hippocampal dysrhythmia and aberrant hippocampal and cortical excitability in the APPswePS1dE9 model of Alzheimer’s disease. Neural Plast 2016:7167358.
30. Persohn E, Malherbe P, Richards JG (1992) Comparative molecular neuroanatomy of cloned GABAA receptor subunits in the rat CNS. J Comp Neur 326:193-216.
31. Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 33:88-109.
32. Pomarol-Clotet E, Honey GD, Murray GK, Corlett PR, Absalom AR, Lee M, McKenna PJ, Bullmore ET, Fletcher PC (2006) Psychological effects of ketamine in healthy volunteers. Phenomenological study. Br J Psychiatry 189:173-179.
33. A receptor subtypes. Nat Rev Drug Discov 10:685-697.
34. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905-1917.
35. Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC, Van Nueten L (2016) Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry 80:424-431.
36. Suzuki T, Aoki T, Kato H, Yamazaki M, Misawa M (1999) Effects of the 5-HT(3)receptor antagonist ondansetron on the ketamine-and dizocilpine-induced place preferences in mice. Eur J Pharmacol 385:99-102.
37. Thompson SM, Kallarackal AJ, Kvarta MD, Van Dyke AM, LeGates TA, Cai X (2015) An excitatory synapse hypothesis of depression. Trends Neurosci 38:279-294.
38. Wolff K, Winstock AR (2006) Ketamine: from medicine to misuse. CNS Drugs 20:199-218.
39. Yuen EY, Wei J, Liu W, Zhong P, Li X, Yan Z (2012) Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 73:962-977.
40. Zanos P, Georgiou P, Wright SR, Hourani SM, Kitchen I, Winsky-Sommerer R, Bailey A (2014) The oxytocin analogue carbetocin prevents emotional impairment and stress-induced reinstatement of opioid-seeking in morphine-abstinent mice. Neuropsychopharmacology 39:855-865.
41. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Gould TD (2016) NMDAR inhibition- independent antidepressant actions of ketamine metabolites. Nature 533:481-486.
42. Zanos P, Piantadosi SC, Wu HQ, Pribut HJ, Dell MJ, Can A, Snodgrass HR, Zarate CA, Schwarcz R, Gould TD (2015) The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineB-site inhibition. J Pharmacol Exp Ther 355:76-85.
43. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Lucken-baugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.